Vimarsana
Biggest News Aggregation in the World

Marc Glickman News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Marc Glickman. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Marc Glickman Today - Breaking & Trending Today

Frederick luthier Marc Glickman begins recording material he's written over a lifetime | Arts & entertainment - Vimarsana News

Frederick luthier Marc Glickman begins recording material he's written over a lifetime | Arts & entertainment

You may know Marc Glickman as one of the area’s premiere luthiers. What you may not know, however, is that he is also a working musician with a handful of

Your aging parents want to stay in their home, but it could be tough - Vimarsana News

Your aging parents want to stay in their home, but it could be tough

Americans are hitting their retirement years, but 90% want to stay in their own homes and not move to a retirement community. It's time to start taking action to make that easier.

Two players, two piano styles - Vimarsana News

Two players, two piano styles

There are lots of great piano players associated with the East Coast. Names like Brendan Dolan, Matt Mulqueen, Donna Long, Helen Kisel, and Annmari...

Hancock Jaffe Laboratories, Inc.: Hancock Jaffe Reports Two CoreoGraft Patients Have Reached 30 Day Milestone - Vimarsana News

Hancock Jaffe Laboratories, Inc.: Hancock Jaffe Reports Two CoreoGraft Patients Have Reached 30 Day Milestone

Hancock Jaffe Laboratories, Inc.: Hancock Jaffe Reports Two CoreoGraft Patients Have Reached 30 Day Milestone IRVINE, CA / ACCESSWIRE / December 16, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that two patients who have undergone heart bypass surgeries utilizing HJLI's CoreoGraft have reached the 30-day milestone and are reported to have good cardiac function. The first two CoreoGraft surgeries were completed in late October and early November, respectively. CoreoGraft patients undergo electro...

Hancock Jaffe Announces Significant Improvements in all Study Endpoints For Final VenoValve First-in-Human Data - Vimarsana News

Hancock Jaffe Announces Significant Improvements in all Study Endpoints For Final VenoValve First-in-Human Data

Share: IRVINE, CA / ACCESSWIRE / December 15, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that the final aggregated data for the VenoValve first-in-human trial shows significant improvements in all study endpoints. For the eleven patients in the first-in-human study, reflux (the backwards flow of blood) improved an average of 54%, disease manifestations as measured by a venous clinical severity scores ("VCSS") improved 56%, and pain, as measured on a visual analog scale ("VAS"), ...